GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InMed Pharmaceuticals Inc (FRA:MWG) » Definitions » EV-to-FCF

InMed Pharmaceuticals (FRA:MWG) EV-to-FCF : 0.03 (As of Apr. 05, 2025)


View and export this data going back to 2004. Start your Free Trial

What is InMed Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, InMed Pharmaceuticals's Enterprise Value is €-0.20 Mil. InMed Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-6.77 Mil. Therefore, InMed Pharmaceuticals's EV-to-FCF for today is 0.03.

The historical rank and industry rank for InMed Pharmaceuticals's EV-to-FCF or its related term are showing as below:

FRA:MWG' s EV-to-FCF Range Over the Past 10 Years
Min: -0.63   Med: 0.44   Max: 0.9
Current: 0.03

During the past 13 years, the highest EV-to-FCF of InMed Pharmaceuticals was 0.90. The lowest was -0.63. And the median was 0.44.

FRA:MWG's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 23.575 vs FRA:MWG: 0.03

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-05), InMed Pharmaceuticals's stock price is €1.70. InMed Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-12.760. Therefore, InMed Pharmaceuticals's PE Ratio (TTM) for today is At Loss.


InMed Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for InMed Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals EV-to-FCF Chart

InMed Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.42 -1.87 -0.15 0.73 0.46

InMed Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 0.64 0.46 0.21 -0.13

Competitive Comparison of InMed Pharmaceuticals's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's EV-to-FCF falls into.


;
;

InMed Pharmaceuticals EV-to-FCF Calculation

InMed Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-0.204/-6.77
=0.03

InMed Pharmaceuticals's current Enterprise Value is €-0.20 Mil.
InMed Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InMed Pharmaceuticals  (FRA:MWG) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

InMed Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.70/-12.760
=At Loss

InMed Pharmaceuticals's share price for today is €1.70.
InMed Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.760.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


InMed Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals Business Description

Traded in Other Exchanges
Address
885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals Headlines